RE: Interesting article:9 Apr 2024 15:01
Yes interesting, but this didn't inspire me with very few patients being treated...
Under the strict guidelines laid down by the US Food & Drug Administration, patients will be dosed individually one month apart, recognising people are being administered with a potentially toxic cells.
Hemogenyx hopes to have the results from “two, or even three patients” in time for the American Society of Hematology conference in early December.